Cart
×
Entrada receives authorization in the United Kingdom to start a Phase 1/2 Duchenne trial skipping exon 45
Entrada trial skipping exon 45 CureDuchenne provided early funding to Entrada Therapeutics, who has announced that they received authorization in the United Kingdom (UK) to initiate a Phase 1/2 multiple […]
Individual with Duchenne dies from acute liver failure after gene therapy treatment
Sarepta Therapeutics has shared that a young man with Duchenne passed away following treatment with ELEVIDYS, an AAV-delivered micro-dystrophin gene therapy. Sarepta has shared that the individual suffered from acute […]
2025 MDA Clinical & Scientific Conference Updates
2025 MDA Conference Updates We’re at the 2025 MDA Clinical & Scientific Conference this week and are pleased to share research updates from companies presenting on the latest advancements in Duchenne muscular […]
Dyne announces new long-term data from DMD clinical trial skipping Exon 51
CureDuchenne provided early funding to Dyne Therapeutics, and is pleased to share that Dyne has released new long-term data from the DELIVER trial in individuals amenable to skipping Exon 51. […]
Avidity announces positive topline data from DMD clinical trial skipping exon 44
CureDuchenne provided early funding to Avidity Biosciences, and are pleased to share they have released positive topline data from the EXPLORE44 trial in individuals amenable to skipping exon 44. Data […]
CureDuchenne Hosts Fourth Annual “Napa in Miami” Wine Tasting and Auction to Help Find a Cure for Duchenne Muscular Dystrophy
Premier Wine Series Will Bring Together Acclaimed Napa Valley Vintners Under One Roof in Miami to Benefit Global Nonprofit CureDuchenne MIAMI, FL, March 12, 2025 – CureDuchenne, a global nonprofit committed […]
CureDuchenne Raises More than $1.1 Million at Napa in Newport and Announces Landmark Partnership with Children’s Hospital of Orange County
Acclaimed Napa Valley Vintners and Philanthropists Come Together to Accelerate Research and Expand Care for Duchenne Muscular Dystrophy NEWPORT BEACH Calif., March 7, 2025– CureDuchenne and Vintner Chairs Morlet Family Vineyards […]
Entrada Therapeutics announces the FDA has removed the clinical hold on ENTR-601-44, their experimental therapeutic designed to skip exon 44
As an early funder of Entrada Therapeutics, we are pleased to share that the FDA has removed the clinical hold on ENTR-601-44, the experimental therapeutic designed for individuals with Duchenne […]